CYCC - Cyclacel Narxning prognoz qilingan daromadga nisbati

Cyclacel, Inc. (CYCC) - korporativ logo

O'zining patent poydevori va klinik ma'lumotlar bazasidan foydalanib, Cyclacel Pharmaceuticals (CYCC) chidamlilikka ega o'smalarga qarshi kurashish uchun og'iz orqali qabul qilinadigan ingibitorlarning hali o'zlashtirilmagan nishasini egallamoqda. Forward P/S tendentsiyasi bozorning kelajakdagi savdolarni qayta baholashini kuzatish imkonini beradi, bunda 1000.60 ushbu metrikaning so'nggi qiymatini aks ettiradi. Ushbu biotexnologik innovator transkripsiya regulyatsiyasi uchun kichik molekulalarni ishlab chiqadi va CDK ingibitorlari sohasida ulkan salohiyatga ega.

Cyclacel Pharmaceuticals, Inc. - CYCC Prognoz narxning daromadga nisbati (davr: 20.08.2023 - 12.09.2025)

Cyclacel, Inc. (CYCC) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- bozor narxi va tahlilchilarning maqsadli narxlari:
Kompaniyaning umumiy tahlili:Cyclacel CYCC
cyclacel.com tomonidan chiqariladigan mahsulotlar

Cyclacel Pharmaceuticals kompaniyasining qattiq o'smalarga qarshi kurashish uchun maqsadli ingibitorlarni ishlab chiqishi kelajakdagi narx-sotuvlar nisbatini dori vositalarini tijoriyashtirishga oid bozor kutuvlarining asosiy ko'rsatkichiga aylantiradi. Ushbu nisbat joriy bozor kapitalizatsiyasini prognoz qilingan daromadlar bilan solishtiradi, bu esa investorlarga aktivning pul oqimini yaratish istiqbollari va umumiy biznes barqarorligiga nisbatan qimmat baholangan yoki arzon baholanganligini baholash imkonini beradi.

Muhim raqobatchilar

Narxning prognoz qilingan daromadga nisbati Incyte INCY|Hutchison MediPharma - Narxning prognoz qilingan daromadga nisbati|NUVB - Narxning prognoz qilingan daromadga nisbati|Bozor kapitallashuvining kelajakdagi daromadga nisbati Day One Biopharmaceuticals Inc|MNPR: Forvard P/S multiplikatori|Prognoz narxning daromadga nisbati inhibrx.com INBX|Forvard narx/daromad multiplikatori IMAB|Bozor kapitallashuvining kelajakdagi daromadga nisbati Fennec Pharma FENC|Forvard narx/daromad multiplikatori HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Sotuvga nisbatan forvard narx|Coherus Biosciences - Forvard narx/daromad multiplikatori|Narxning kutilayotgan daromadga nisbati CRBP (corbuspharma.com)|Cardiff Oncology Corp - Forvard P/S multiplikatori|Sotuvga nisbatan forvard narx BYSI (BeyondSpring, Inc.)|BCAB: Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Lixte Biotechnology, Inc. (LIXT)|Narxning prognoz qilingan daromadga nisbati Citius Pharmaceuticals Inc.|CLRB: Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori BLRX|Forvard P/S multiplikatori Can-Fite BioPharma Ltd (CANF)|Narxning prognoz qilingan daromadga nisbati Aprea Therapeutics, Inc. APRE|KZIA (Kazia Therapeutics Ltd) - Kelajakdagi narxning daromadga nisbati|SLXN: Forvard narx/daromad multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati NuCana plc|CMRX: Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori G1 Therapeutics|Forvard narx/daromad multiplikatori KRON|Bozor kapitallashuvining kelajakdagi daromadga nisbati Kintara Pharma KTRA|Forvard P/S multiplikatori ONCT|Forvard narx/daromad multiplikatori portagebiotech.com PRTG